Vertex Pharmaceuticals Inc (NASDAQ:VRTX) shares are rising in extended trading Monday after the company announced positive interim results for one of its Phase 3 trials. Vertex Pharmaceuticals stock is trading in a tight range. What’s next for VRTX stock?Vertex Reports Positive Results For All EndpointsVertex announced positive data from a pre-specified week 36 interim analysis of its ongoing phase 3 RAINIER trial of povetacicept in immunoglobulin A nephropathy.Povetacicept is an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. The trial met its primary objective, achieving a 52% reduction ...Full story available on Benzinga.com
Vertex Pharmaceuticals Stock Jumps After The Close: Here's Why
